Skip to main content

Table 2 Clinical and demographic features of RespondersT13 and NON-RespondersT13

From: Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

  Total RespondersT13 NON-RespondersT13 p-value
n 77 50 27 -
Age, (years, m ± sd) 49.8 ± 9.5 49.4 ± 9.4 50.6 ± 9.7 0.967
Females, n (%) 55 (71.4) 33 (66.0) 22 (81.5) 0.191
Age at headache onset (years, m ± sd) 14.5 ± 6.9 15.0 ± 7.3 13.6 ± 6.2 0.300
Years lived with migraine (years, m ± sd) 35.6 ± 10.8 34.8 ± 10.5 36.9 ± 11.2 0.701
Years lived with chronic migraine (years, m ± sd) 13.1 ± 10.3 12.6 ± 10.0 14.2 ± 12.6 0.424
Migraine with aura, n (%) 13 (16.9) 10 (20.0) 3 (11.1) 0.525
MOH, n (%) 71 (92.2) 40 (95.2) 31 (88.6) 0.402
Previous detoxification for MOH, n (%) 69 (89.6) 45 (90.0) 24 (88.9) 0.879
Preventive treatment
 Patients on preventive treatment at T0, n (%) 42 (54.5) 28 (56.0) 14 (51.9) 0.812
 Number of previously failed preventive treatments (m ± sd) 3.8 ± 1.2 3.7 ± 1.3 4.0 ± 1.0 0.439
 Previous BoNT-A treatment, n (%) 47 (61.0) 27 (54.0) 20 (74.1) 0.094
Classes of acute drugs
 NSAIDs, n (%) 12 (15.6) 7 (16.7) 5 (14.3) 0.408
 Triptans, n (%) 20 (26.0) 9 (21.4) 11 (31.4)
 Combination, n (%) 4 (5.2) 1 (2.4) 3 (8.6)
 Multiple drug classes, n (%) 41 (53.2) 25 (59.5) 16 (45.7)
Comorbidities
 Hypertension, n (%) 19 (24.7) 11 (26.2) 8 (22.9) 0.795
 Anxiety, n (%) 22 (28.6) 12 (28.6) 10 (28.6) 0.999
 Depression, n (%) 4 (5.2) 2 (4.8) 2 (5.7)
 Anxiety and depression, n (%) 18 (23.4) 10 (12.9) 8 (10.3)
 vInsomnia, n (%) 33 (42.9) 18 (42.9) 15 (42.9) 1.000
Migraine features at baseline
 Monthly headache days (m ± sd) 24.6 ± 4.8 24.3 ± 4.9 25.2 ± 4.6 0.545
 Monthly migraine days (m ± sd) 23.0 ± 5.1 22.9 ± 4.9 23.1 ± 5.4 0.861
 Monthly days of acute drugs intake (m ± sd) 20.8 ± 7.6 21.0 ± 7.3 20.3 ± 8.2 0.534
 Monthly doses of acute drugs intake (m ± sd) 34.7 ± 29.9 33.8 ± 28.6 36.3 ± 32.6 0.898
Questionnaires at baseline
 MIDAS (m ± sd) 77.5 ± 69.0 74.0 ± 70.7 84.0 ± 66.5 0.452
 Mean headache intensity (m ± sd) 8.0 ± 6.4 8.3 ± 7.9 7.5 ± 1.1 0.349
 HIT-6 (m ± sd) 66.8 ± 5.8 66.0 ± 5.7 68.3 ± 5.6 0.113
 ASC-12 (allodynia) (m ± sd) 6.4 ± 5.1 6.1 ± 5.5 6.8 ± 4.4 0.707
 MSQ (m ± sd) 34.4 ± 18.1 36.8 ± 16.0 29.7 ± 21.0 0.190
 General Health (0–100) (m ± sd) 54.4 ± 22.3 59.2 ± 19.4 45.6 ± 2 4.9 0.022
 HADS-A (m ± sd) 6.51 ± 4.03 6.0 ± 3.9 7.4 ± 4.1 0.079
 HADS-D (m ± sd) 6.39 ± 4.40 5.6 ± 4.3 7.8 ± 4.3 0.031
  1. Legend: RespondersT13: Patients with a MMDs reduction from baseline of at least 50% in the last 4 weeks of observation period (after 13 erenumab administrations). NON-RespondersT13: Patients with a MMDs reduction from baseline < 50% in the last 4 weeks of observation period (after 13 erenumab administrations).
  2. CM Chronic migraine, CM + MOH Chronic migraine and medication overuse headache, BoNT-A Onabotulinumtoxin-A, MIDAS MIgraine Disability Assessment, HIT-6 Headache Impact Test-6, ASC-12 Allodynia Symptoms Checlist, MSQ Migraine-Specific Quality of Life Questionnaire, HADS Hospital Anxiety and Depression Scale. Data are presented as means ± standard deviations (m ± sd) or absolute values (percentages).